Stay updated with breaking news from Double Blind. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Prothione capsules were safe and well tolerated Subjects with mild to moderate COVID-19 symptoms on Prothione experienced more rapid clinical resolution Patients with moderate to severe symptoms of COVID-19 on Prothione were 4 times less likely to be admitted to the hospital than those on placebo FRANKLIN, Tenn.--(BUSINESS WIRE)--Prothione LLC,…
SAN FRANCISCO and SUZHOU, China, June 8, 2022 /PRNewswire/ --Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announces that the primary and all key secondary endpoints were met in a randomized, double-blind, placebo-controlled phase 2 study of mazdutide (R&D code: IBI362), a glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR) dual agonist, in Chinese participants with ove...
SAN FRANCISCO and SUZHOU, China, June 13, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the results of high-dose cohorts in a phase 1 clinical trial of mazdutide (IBI362), a glucagon-like petide-1 (GLP-1) and glucagon receptor dual agonist, in Chinese adults with overweight or obesity are presented as an on-demand poster (ODP014) at ENDO 202...
-- Oral presentation on KRYSTEXXA (pegloticase injection) plus methotrexate to be held June 2, 2022 at 11:35 a.m. CEST-- -- Additional data presentations provide new insights on psychosocial and
Blackrock man Ian Hunt-Duffy fell in love with film at a young age, fascinated by behind the camera film documentaries and recreating scenes from his favourite ...